scholarly journals Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Monireh Mohsenzadegan ◽  
Mahdieh Razmi ◽  
Somayeh Vafaei ◽  
Maryam Abolhasani ◽  
Zahra Madjd ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Histological Grade ◽  
Immunohistochemical Analysis ◽  
Tumor Aggressiveness ◽  
P Values ◽  
Normal Tissues ◽  
Cancer Testis Antigens ◽  
Clinicopathological Significance ◽  
The Common ◽  
Cancer Testis

AbstractMelanoma antigen gene (MAGE)-A6 and MAGE-A11 are two of the most cancer-testis antigens overexpressed in various types of cancers. However, the clinical and prognosis value of MAGE-A6 and MAGE-A11 co-expression in the pathophysiology of the bladder is unknown. Three studies were selected from GEO databases in order to introduce the common genes that are involved in bladder cancer. Then immunohistochemical analysis for staining pattern and clinicopathological significance of suggested markers, MAGE-A6 and MAGE-A11, were performed in 199 and 213 paraffin-embedded bladder cancer with long adjacent normal tissues, respectively. A significant and positive correlation was found between both nuclear and cytoplasmic expressions of MAGE-A6 as well as expression of cytoplasmic MAGE-A11 with histological grade, PT stage, lamina propria invasion, and LP/ muscularis (L/M) involvement (all of the p-values in terms of H-score were < 0.0001). Additionally, significant differences were found between both nuclear and cytoplasmic MAGE-A6/MAGE-A11 phenotypes with tumor size (P = 0.007, P = 0.043, respectively), different histological grades, PT stage, LP involvement, and L/M involvement (all of the p-values for both phenotypes were < 0.0001). The current study added the value of these novel markers to the bladder cancer clinical settlement that might be considered as an admirable target for immunotherapy.

FADS1 is a Prognostic Biomarker in Bladder Cancer: A Study Based on TCGA Data

2020 ◽  
Vol 23 ◽  
Author(s):  
Ying Lu ◽  
Jing Shao ◽  
Xu Shu ◽  
Yaofei Jiang ◽  
Jianfang Rong ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Histological Grade ◽  
Clinical Stage ◽  
Fatty Acid Desaturase ◽  
Clinical Information ◽  
The Cancer Genome Atlas ◽  
Cancer Prognosis ◽  
Normal Tissues ◽  
Potential Biomarker ◽  
T Classification

Aim and Objective: Fatty acid desaturase 1 (FADS1) has been reported to be a potential biomarker in various cancers. However, no study has explored the relationship between FADS1 expression and bladder cancer. Our study aimed to investigate the role of FADS1 in bladder cancer prognosis via The Cancer Genome Atlas (TCGA). Materials and Methods: RNA-Seq expression of 414 tumor tissues and 19 paired normal tissues, as well as corresponding clinical data, were downloaded from TCGA database. Two cancer cases were excluded due to a lack of clinical information. The association between FADS1 and the clinicopathological features of bladder cancer was analyzed. This study was conducted in October of 2019 in China. Results: The high expression of FADS1 in bladder cancer was significantly related to histological grade (OR = 0.155 for low vs. high), clinical stage (OR=2.074 for III or IV vs. I or II), T classification (OR=2.326 for T3 or T4 vs. T1 or T2), lymphatic metastasis (OR=1.923 for N1 or N2 or N3 vs. N0) and distant metastasis (OR=4.883 for yes vs. no) (all p-values <0.05). Bladder cancer with high FADS1 levels was related to a worse prognosis than bladder cancer with low FADS1 levels (p= 1.626*10-5 ), according to median expression value 3.622. FADS1 was an independent factor of overall survival in bladder cancer, with a hazard ratio of 1.048 (95%CI: 1.020–1.077, p = 0.001). Conclusions: Increased FADS1 expression in bladder cancer is associated with advanced clinical pathological features and may be a potential biomarker for poor prognosis.

Expression of SSX-2 and SSX-4 Genes in Neuroblastoma

2002 ◽  
Vol 17 (4) ◽  
pp. 219-223 ◽  
Author(s):  
S.N. Chi ◽  
N.-K.V. Cheung ◽  
I.Y. Cheung
Keyword(s):  
Cytolytic T Lymphocytes ◽  
Rt Pcr ◽  
Normal Peripheral Blood ◽  
Normal Tissues ◽  
Cancer Testis Antigens ◽  
Stage 4 ◽  
The Family ◽  
Prognostic Utility ◽  
Stage 1 ◽  
Cancer Testis

The SSX genes are members of the family of cancer/testis antigens that encode tumor-associated antigens recognizable by autologous cytolytic T lymphocytes. Their expression is common in tumors of diverse lineages and absent in normal tissues except testis and thyroid. In this study, sixty-seven neuroblastomas (NB) (12 stage 1, 13 stage 2, 12 stage 3, 12 stage 4S and 13 stage 4) were examined by RT-PCR and a sensitive chemiluminescent detection method for SSX-2 and SSX-4 expression. Seventy-two percent (13/18) of stage 4 NB expressed SSX-2 and 67% (12/18) expressed SSX-4. SSX-2 and SSX-4 positivity correlated with metastatic NB stage 4 (p=0.02 and p=0.006, respectively). Sensitivity experiments showed SSX-2 detection was one tumor cell in 106 normal cells, and one in 104 for SSX-4. All normal tissues (n=6), with the exception of testis, normal bone marrow (BM, n=12) and normal peripheral blood (PBL, n=10) were negative for SSX-2 and SSX-4 expression. Thirty-two BM and 14 PBL obtained from 35 stage 4 NB patients at 24 months from their diagnosis were evaluated for SSX-2 expression. Unlike another cancer/testis antigen, GAGE, only one BM sample was positive, and no prognostic utility could be established. Further investigation of SSX expression at other relevant time points is warranted.

Prognostic Impact of Cancer Testis Antigens Expression in Advanced Stage Multiple Myeloma Patients.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4733-4733 ◽  
Author(s):  
Valéria C.C. Andrade ◽  
André L. Vettore ◽  
Manuella S.S. Almeida ◽  
José S.R. Oliveira ◽  
Maria de Lourdes L.F. Chauffaille ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cell Line ◽  
Prognostic Impact ◽  
Advanced Stage ◽  
Normal Tissues ◽  
Cancer Testis Antigens ◽  
Three Samples ◽  
Cox's Regression ◽  
Ct Antigens ◽  
Cancer Testis

Abstract Background: Cancer testis antigens have become the most extensively studied antigen group in the field of tumor immunology. Aims: This study aims to analyze global expression of 14 CT (cancer/testis) antigens in MM to identify possible prognostic markers and therapeutic targets. Patients and Methods: The expression of MAGEA1, MAGEA2, MAGEA3/6, MAGEA4, MAGEA10, MAGEA12, BAGE1, MAGEC1/CT7, GAGE family, LAGE-1, PRAME, NY-ESO-1, SPA17 and SSX1 was studied by RT-PCR in: 15 normal tissues, one pool of 10 normal bone marrow samples, three normal tonsils and bone marrow aspirates from six normal donors, three monoclonal gammophaties of undetermined significance (MGUS), five solitary plasmacytomas, 39 MM samples (95% advanced stage) and MM cell line U266. CodeLink Human UniSet I Bioarrays 10,000 genes was used for arrays analyses. Results: SPA17 was positive in all normal tissues and was excluded for further analyses. MAGEC1/CT7 was positive in bone marrow aspirates from one MGUS and in one plasmacytoma. U266 cell line was positive for all CT antigens, except SSX1. The frequencies of CT antigens expression in MM patients were: MAGEC1/CT7 = 30/39 (77%); LAGE-1 = 19/39 (49%); MAGEA3/6 = 16/39 (41%); MAGEA2 = 14/39 (36%); GAGE family = 13/39 (33%); NY-ESO-1 = 13/39 (33%); BAGE-1 = 12/39 (28%); MAGEA1 = 10/39 (26%); PRAME = 9/39 (23%); SSX-1 = 10/39 (26%); MAGEA12 = 8/39 (20.5%); MAGEA4 and MAGEA10 = 0%. Cox’s regression model showed that GAGE family positivity and number of positive CT antigens > 6 were independent prognostic factors when all patients were analyzed. However, MAGEC1/CT7 expression was the only independent prognostic factor when non-transplanted patients where analyzed. Three samples predominantly positive (> 6) and three samples predominantly negative (0 or 1) for the 13 analyzed CT antigens were submitted to microarrays analyses. 147 genes were overexpressed in predominantly positive CT antigens samples. Conclusions: Based on our findings, MAGEC1/CT7, MAGEA3/6 and LAGE-1 seem good candidates for immunotherapy, since together they are overexpressed in 85% of our MM cases. Besides, GAGE family expression, number of CT antigens > 6 and MAGEC1/CT7 seem to have impact on MM prognosis. Also, the results of arrays analyses corroborate the hypothesis that MM can be separate in two groups: predominantly positive and predominantly negative for CT antigens, meaning that these antigens may have important role for MM biology.

scholarly journals Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma

2013 ◽  
Vol 11 (1) ◽  
Author(s):  
Tvrtko Hudolin ◽  
Zeljko Kastelan ◽  
Ivana Ilic ◽  
Katarina Levarda-Hudolin ◽  
Nikolina Basic-Jukic ◽  
...  
Keyword(s):  
B Cell ◽  
Immunohistochemical Analysis ◽  
Cancer Testis Antigens ◽  
Testicular Lymphoma ◽  
Large B Cell ◽  
Cancer Testis

scholarly journals Nuclear Localization of COX-2 in relation to the Expression of Stemness Markers in Urinary Bladder Cancer

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Raynoo Thanan ◽  
Mariko Murata ◽  
Ning Ma ◽  
Olfat Hammam ◽  
Mohamed Wishahi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Nuclear Localization ◽  
Cytoplasmic Membrane ◽  
Immunohistochemical Analysis ◽  
Urinary Bladder Cancer ◽  
Normal Tissues ◽  
Cox 2 ◽  
Cancer Tissues ◽  
Cd44v6 Expression

Inflammation may activate stem cells via prostaglandin E2 (PGE2) production mediated by cyclooxygenase-2 (COX-2) expression. We performed an immunohistochemical analysis of the expression of stemness markers (Oct3/4 and CD44v6) and COX-2 in urinary bladder tissues obtained from cystitis and cancer patients with and withoutSchistosoma haematobiuminfections. Immunoreactivity to Oct3/4 was significantly higher inS. haematobium-associated cystitis and cancer tissues than in normal tissues. CD44v6 expression was significantly higher in bladder cancer withoutS. haematobiumthan in normal tissues. COX-2 was located in the cytoplasmic membrane, cytoplasm, and nucleus of the cancer cells. Interestingly, the nuclear localization of COX-2, which was reported to function as a transcription factor, was significantly associated with the upregulation of Oct3/4 and CD44v6 in bladder cancer tissues with and withoutS. haematobiuminfection, respectively. COX-2 activation may be involved in inflammation-mediated stem cell proliferation/differentiation in urinary bladder carcinogenesis.

Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, An Immunogenic Cancer Testis Antigen

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4207-4207
Author(s):  
Jason A Dubovsky ◽  
Douglas G McNeel ◽  
John J. Powers ◽  
Eduardo M. Sotomayor ◽  
Javier Pinilla
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Antigen Presentation ◽  
Lymphocytic Leukemia ◽  
Active Immunotherapy ◽  
Aberrant Expression ◽  
Normal Tissues ◽  
Cancer Testis Antigens ◽  
Solid Malignancies ◽  
Specific Proteins ◽  
Cancer Testis

Abstract Critical to success of active immunotherapy against cancer is the identification of immunologically recognized cancer-specific proteins with low tolerogenic potential. Cancer testis antigens (CTAs) in particular, fulfill this requirement as a result of their aberrant expression restricted to cancer cells and lack of expression in normal tissues bypassing tolerogenic mechanisms against self. Although CTAs have been extensively studied in solid malignancies little is known regarding their expression in chronic lymphocytic leukemia (CLL). Using a two-pronged approach we evaluated the immunogenicity of 29 CTAs in 22 patients with CLL and correlated these results to RTPCR data from CLL cell lines and patient cells. We identified IgG specific antibodies for one antigen, NXF2 and confirmed this response by ELISA and Western blot. We found that treatment of CLL with 5-aza-2′-deoxycytidine can induce expression of NXF2 that lasted for several weeks after treatment. Treatment also increased levels of MHC and costimulatory molecules (CD80, CD86, and CD40) necessary for antigen presentation. In addition, we identified other promising antigens such as NY-ESO-1 and MAGE which may have potential immunotherapeutic application. Our findings suggest that NXF2 could be further pursued as an immunotherapeutic target in CLL, and that treatment with demethylating agents could be exploited to specifically modulate CTA expression and effective antigen presentation in malignant B-cells.

Validation of immunogenic PASD1 peptides against HLA-A*24:02 colorectal cancer

Immunotherapy ◽  
2019 ◽  
Vol 11 (14) ◽  
pp. 1205-1219 ◽  
Author(s):  
Joanne EC Soh ◽  
Nadiah Abu ◽  
Ismail Sagap ◽  
Luqman Mazlan ◽  
Azyani Yahaya ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Treatment Options ◽  
Rt Pcr ◽  
Normal Tissues ◽  
Cancer Testis Antigens ◽  
Protein Expressions ◽  
Mrna And Protein Expression ◽  
Polymerase Chain ◽  
Cancer Testis

Colorectal cancer is the third commonest malignancy in Asia including Malaysia. The immunogenic cancer-testis antigens, which are expressed in a variety of cancers but with limited expression in normal tissues except the testis, represent an attractive approach to improve treatment options for colorectal cancer. We aimed to validate four PASD1 peptides as the immunotherapeutic targets in colorectal cancer. First, PASD1 mRNA and protein expression were determined via real-time polymerase chain reaction (RT-PCR) and immunohistochemistry. The PASD1 peptides specific to HLA-A*24:02 were investigated using IFN-y-ELISpot assay, followed by the cytolytic and granzyme-B-ELISpot assays to analyze the cytolytic effects of CD8+ T cells. Gene and protein expressions of PASD1 were detected in 20% and 17.3% of colorectal cancer samples, respectively. PASD1(4) peptide was shown to be immunogenic in colorectal cancer samples. CD8+ T cells raised against PASD1(4) peptide were able to lyze HLA-A*24:02+ PASD1+ cells. Our results reveal that PASD1(4) peptide represents a potential target for colorectal cancer.

Expression analysis of a panel of cancer-testis antigens in bladder cancer

2018 ◽  
Vol 15 (6) ◽  
pp. 511-520 ◽  
Author(s):  
Fatemeh Yazarlou ◽  
Vahid Kholghi-Oskooei ◽  
Mandana Afsharpad ◽  
Leila Nekoohesh ◽  
Tamouchin Moharrami ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Expression Analysis ◽  
Cancer Testis Antigens ◽  
Cancer Testis

scholarly journals High LINC01605 expression predicts poor prognosis and promotes tumor progression via up-regulation of MMP9 in bladder cancer

2018 ◽  
Vol 38 (5) ◽  
Author(s):  
Zhiqiang Qin ◽  
Yi Wang ◽  
Jingyuan Tang ◽  
Lei Zhang ◽  
Ran Li ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Survival Analysis ◽  
Signaling Pathway ◽  
High Throughput Sequencing ◽  
Epithelial Mesenchymal Transition ◽  
Histological Grade ◽  
Migration And Invasion ◽  
Mesenchymal Transition ◽  
Normal Tissues

The advent of high-throughput sequencing methods has facilitated identification of novel long non-coding RNAs (lncRNAs), which have been demonstrated to play an important role in multiple tumors. Moreover, with the assistance of bioinformatics analysis, LINC01605 has been found to be up-regulated in bladder cancer (BC) tissues compared with normal tissues. Hence, the present study was to explore its specific biological role and related mechanism in BC. The relative expression level of LINC01605 was measured in a cohort of BC tissues with matched normal tissues as well as human BC cell lines by quantitative real-time PCR (qRT-PCR). Survival analysis was performed to explore the relationship between LINC01605 expression and the prognosis of BC patients. The biological function of LINC01605 was studied in vitroand in vivo, by means of CCK-8 assay, colony formation assay, transwell assay, and tumor xenografts mice model. LINC01605 was found to be frequently highly expressed in both human BC cells and tissues. Survival analysis indicated that high LINC01605 expression was associated with higher histological grade and clinical stages. In addition, down-regulated LINC01605 in BC cells could significantly inhibit the abilities of proliferation, migration, and invasion in vitro and knockdown of LINC01605 in subcutaneous xenograft tumor model could impede tumorigenesis in vivo. Mechanistically, LINC01605 could activate epithelial–mesenchymal transition (EMT) signaling pathway and promote the expression of matrix metallopeptidase (MMP) 9 (MMP9). In summary, our results shed light on that LINC01605, as a new prognostic biomarker, could promote the proliferation, migration, and invasion of BC cells via activating EMT signaling pathway and up-regulating MMP9 expression.

Sign in / Sign up

Export Citation Format

Share Document